RECRUITINGOBSERVATIONAL
Molecular Mechanisms in Malignant Lymphoma- Predict (MMML Predict)
Molecular Mechanisms in Malignant Lymphoma- Predict
About This Trial
The trial aims at the construction and validation of an accurate, affordable and simple prognostic tool to be used in everyday clinical practice, which allows the early and reliable identification of DLBCL patients who have a very high risk of treatment failure following R-CHOP/-like first-line therapy.
Who May Be Eligible (Plain English)
Who May Qualify:
1. Histological diagnosis of DLBCL\&LBCL
2. Planned treatment with guideline-based first-line therapy
3. Patient's consent
4. All genders, Patient age ≥ 18 years
5. Ability to consent
Who Should NOT Join This Trial:
1. Treatment with R-CHOP/-like regimens already started
2. Relationship of dependence/ direct employment with the investigator
3. Active HIV-infection
4. Presence history of other active cancers (with the exception of basal cell carcinoma of the skin)
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion Criteria:
1. Histological diagnosis of DLBCL\&LBCL
2. Planned treatment with guideline-based first-line therapy
3. Patient's consent
4. All genders, Patient age ≥ 18 years
5. Ability to consent
Exclusion Criteria:
1. Treatment with R-CHOP/-like regimens already started
2. Relationship of dependence/ direct employment with the investigator
3. Active HIV-infection
4. Presence history of other active cancers (with the exception of basal cell carcinoma of the skin)
Treatments Being Tested
OTHER
no intervention
no intervention
Locations (1)
Universitätsmedizin Göttingen
Göttingen, Lower Saxony, Germany